ArticleBMC gastroenterology2026
Analysis of survival prognosis and influencing factors in patients with primary liver cancer after D-TACE: a retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveTransarterial chemoembolization (TACE) has become the standard treatment for moderately advanced hepatocellular carcinoma (HCC), but there are significant differences in postoperative survival rates, and the key factors influencing prognosis remain unclear. This article focuses on exploring the prognostic factors that affect the progression-free survival (PFS) and overall survival (OS) of patients with primary hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (D-TACE).
methodsA retrospective cohort study design was adopted. A total of 114 HCC patients who received their first D-TACE treatment at our hospital from January 2021 to December 2023 and were followed up (with a follow-up period of 6 to 36 months) were included. Baseline data were collected, and survival rates were calculated using the Kaplan-Meier method and survival curves were plotted. Log-rank test was used for inter-group comparison. Multivariate analysis was conducted using methods such as Cox proportional hazards regression analysis to screen independent prognostic factors.
resultsThe patients were divided into the survival group and the death group based on their survival status after 36 months. We found that there were significant differences in baseline characteristics such as the maximum tumor diameter, portal vein invasion, extrahepatic metastasis, CNLC stage, BCLC stage, ECOG score, liver function classification (Child-pugh score), multiple tumor foci, BMI, and several serum indicators between the survival group (46 cases) and the death group (68 cases) (P < 0.05). The KM survival analysis showed that the differences in PFS and OS between the two groups were statistically significant (Log-rank P < 0.001). Multivariate Cox analysis indicated that the maximum tumor diameter of the lesion (HR = 1.08, 95% CI: 1.01-1.18, P = 0.049) and portal vein invasion (HR = 1.99, 95% CI: 1.09-3.64, P = 0.025), ECOG score (HR = 1.91, 95% CI: 1.05-3.50, P = 0.035) were independent risk factors for PFS. Portal vein invasion (HR = 3.22, 95% CI: 1.66-6.26, P < 0.001) and HB (HR = 0.99, 95% CI: 0.97-0.99, P = 0.044), NLR (HR = 1.25, 95% CI: 1.02-1.53, P = 0.035) were independent risk factors for OS.
conclusionsThis study found that the maximum diameter of the tumor, invasion of the portal vein, and ECOG score were independent predictors of disease progression in HCC patients after D-TACE surgery. Meanwhile, invasion of the portal vein and HB, NLR were key factors affecting the overall survival of patients. In clinical practice, these indicators should be comprehensively evaluated. For high-risk patients, enhanced follow-up management and active consideration of combined systemic treatment and other comprehensive strategies should be adopted to improve their prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.